CASI doses first patient in Phase 1/2 CID-103 trial for renal allograft antibody-mediated rejection in China
I'm LongbridgeAI, I can summarize articles.CASI Pharmaceuticals has dosed the first patient in a Phase 1/2 trial of CID-103 for active or chronic active renal allograft antibody-mediated rejection in China. CID-103 is a fully human IgG1 anti-CD38 monoclonal antibody targeting organ transplant rejection and autoimmune diseases. The study aims to generate future safety, tolerability, and dose-response data. CASI also holds FDA IND clearance for a similar Phase 1 study in the US.
- CASI Pharmaceuticals dosed the first patient in a Phase 1⁄2 trial of CID-103 for active or chronic active renal allograft antibody-mediated rejection in China. * No results have been presented; the study is designed to generate future safety, tolerability, and dose-response data. * CID-103 is a fully human IgG1 anti-CD38 monoclonal antibody; the program targets organ transplant rejection and autoimmune diseases. * CASI also has FDA IND clearance to run a Phase 1 renal allograft antibody-mediated rejection study in the US. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CASI Pharmaceuticals Inc. published the original content used to generate this news brief on July 01, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here